ީӄ⎏⊕ђᯯะഖ⭕⢟㛗Գᴿ䲆ޢਮ ֵ⭞䜞࠼Ჸᰬ䰨㖤क䳼䍺䠇䘑㺂⧦䠇㇗⨼ⲺṮḛᝅ㿷 ݹབྷ䇱ࡨ㛑ԭᴹ䲀ޜਨ˄ԕлㆰ〠Āݹབྷ䇱ࡨāᡆĀ؍㦀ᵪᶴā˅Ѫ⎉⊏ ьᯩสഐ⭏⢙ࡦ૱㛑ԭᴹ䲀ޜਨ˄ԕлㆰ〠Āьᯩ⭏⢙āᡆĀޜਨā˅俆⅑ޜᔰ ਁ㹼㛑⾘ᒦ൘、ࡋᶯкᐲ৺䘋㹼ᤱ㔝ⶓሬⲴ؍㦀ᵪᶴˈṩᦞlj䇱ࡨਁ㹼кᐲ؍㦀 ъ࣑⨶㇑࣎˄⌅ ᒤ؞䇒˅NJljкᐲޜਨⴁ㇑ᤷᕅㅜ ਧüüкᐲޜਨए䳶䍴 䠁㇑⨶઼֯⭘Ⲵⴁ㇑㾱≲˄ ᒤ؞䇒˅NJljк⎧䇱ࡨӔ᱃ᡰ、ࡋᶯ㛑⾘кᐲ㿴 ࡉ˄ ᒤ ᴸ؞䇒˅NJljк⎧䇱ࡨӔ᱃ᡰ、ࡋᶯкᐲޜਨ㠚ᖻⴁ㇑ᤷᕅㅜ ਧ üü㿴㤳䘀˄ ᒤ ᴸ؞䇒˅NJㅹᴹޣ⌅ᖻ⌅㿴઼㿴㤳ᙗ᮷ԦⲴ㾱≲ˈሩ ьᯩ⭏⢙ᤏ֯⭘䜘࠶Ჲᰦ䰢㖞ए䳶䍴䠁䘋㹼⧠䠁㇑⨶һ亩䘋㹼ҶṨḕˈᒦਁ㺘Ṩ ḕ㿱ྲл˖ жȽᵢ⅗क䳼䍺䠇Ⲻะᵢ߫ ਮޢ㛗Գᴿ䲆ཝ䇷ݿ 㓿ѝഭ䇱ࡨⴁⶓ㇑⨶ငઈՊljޣҾ਼⎉⊏ьᯩสഐ⭏⢙ࡦ૱㛑ԭᴹ䲀ޜਨ 俆⅑ޜᔰਁ㹼㛑⾘⌘Ⲵᢩ༽NJ˄䇱ⴁ䇨ਟǏǐ ਧ˅᮷਼ˈޜਨੁ⽮ Պޜᔰਁ㹼Ӫ≁ᐱᲞ䙊㛑˄$ 㛑˅㛑⾘ з㛑ˈ⇿㛑ਁ㹼ԧṬ ݳˈᡚ 㠣 ᒤ ᴸ ᰕˈޜਨए䳶䍴䠁ᙫ仍 ӯݳˈए䳶䍴䠁߰仍 ӯ ݳDŽк䘠ए䳶䍴䠁ࡠսᛵߥᐢ㓿・ؑՊ䇑ᐸһ࣑ᡰ˄⢩ ...

证券代码：688298 证券简称：东方生物 公告编号：2024-069 根据公司《首次公开发行股票并在科创板上市招股说明书》，公司首次公开 1 公司募集资金投资项目全部建设完结尚需要一定的时间周期，短期内存在部 分暂时闲置募集资金的情形。 浙江东方基因生物制品股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2024 年 12 月 27 日浙江东方基因生物制品股份有限公司（以下简称"东方 生物""公司"或"发行人"）召开第三届董事会第十一次会议，以 7 票同意、 0 票反对、0 票弃权的表决结果审议通过了《关于使用部分暂时闲置募集资金进 行现金管理的议案》，于同日召开的第三届监事会第十次会议以 3 票同意、0 票 反对、0 票弃权的表决结果审议通过了《关于使用部分暂时闲置募集资金进行现 金管理的议案》，同意公司使用额度不超过人民币 7,500.00 万元的部分暂时闲置 募集资金在确保不影响募集资金投资项目进度、确保资金安全的情况下，合理利 用暂时闲置募集资金进行 ...

浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 及全资子公司哈尔滨东方基因生物制品有限公司（以下合并简称"公司"）近期 取得以下几款主要产品的国内医疗器械认证证书，相关公告如下： | 产品名称 | 证书编号 | 预期 | 授权日期, | | --- | --- | --- | --- | | | | 用途 | 有效期 | | 多项毒品联合检测试剂盒（胶 | 国械注准 | 本产品用于体外定性检测人体尿液中包 | 2024/12/13 | | | | 含吗啡、甲基安非他明、氯胺酮、可卡因 | | | 体金法） | 20243402487 | 代谢物苯甲酰爱康宁、二亚甲基双氧安非 | 5年 | | | | 他明、四氢大麻酚酸的初筛检测 | | | 胱抑素C检测试剂盒（时间分 | 黑械注准 | 用于体外定量检测人血清、血浆或全血中 | | | β2-微球蛋白检测试剂盒（时 | 黑械注准 | 用 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-066 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 全资子公司美国衡健生物科技有限公司（以下简称"美国衡健"）近日取得毒品 尿杯联合检测试剂（专业/自测）的美国食品药品监督管理局FDA 510(K)许可证； 东方生物的新冠/甲乙流抗原三联检试剂（专业/自测）近日取得欧盟IVDR注册证 书，相关内容公告如下： | 产品名称 | 证书 | 预期 | 生效 | | --- | --- | --- | --- | | | 类型 | 用途 | 日期 | | Healgen® Accurate Muti-Drug Urine | | | | | Drug Screen Cup 毒品尿杯联合检测试剂（专业） | 美国FDA 510(K) | 可采用尿液样本，用于定性检测包含 | | | | | 芬太尼，甲基安非他命等十八个种类 | ...

浙江东方基因生物制品股份有限公司 关于全资子公司竞得土地使用权暨对外投资进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688298 证券简称：东方生物 公告编号：2024-065 浙江东方基因生物制品股份有限公司（以下简称"东方生物""东方基因" 或"公司"）于 2024 年 10 月 29 日召开了第三届董事会第十次会议，审议通过 了《关于对外投资的议案》，同意公司以下属全资子公司上海万山水生物科技有 限公司（以下简称"上海万山水"）作为建设主体，在上海张江民营企业总部集 聚区 E13-02 地块投资建设"东方基因全球数字化研发创新总部项目"，计划项 目投资额 15 亿元，固定资产投资 12 亿元，配套流动资金 3 亿元，总用地面积 23,499.00(平方米),总建筑面积 13 万平方米，拟竣工时间 2028 年 3 月，预计达 产年度销售收入 15 亿元，达产年度纳税 1.5 亿元。 本项目投资以合法取得本项目选址用地，以及完成各项建设许可/备案/批复 等合法手续，作为本项目实施的前置条件，以正 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-064 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证及新兽药证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 全资子公司美国衡健生物科技有限公司（以下简称"美国衡健"）的新冠抗原检 测试剂（专业版）取得的CLIA证书近日生效，同时获得加拿大医疗器械注册证； 控股子公司杭州莱和生物技术有限公司（简称"杭州莱和"）的四款毒品检测试 剂近日取得由国家药品监督管理局（以下简称"NMPA"）颁发的《医疗器械注册 证》（体外诊断试剂）；另外，公司参与研制或生产的两款动物检测试剂被纳入 由中华人民共和国农业农村部审查批准核发的新兽药注册目录/兽药产品目录，相 关内容公告如下： 一、CLIA证书的基本情况 二、医疗器械注册证的基本情况 | 产品名称 | 证书 | | 预期 | 授权 日期.有效 | | --- | --- | --- | --- | --- | | | 编号 | ...

Core Viewpoint - The achievement of FDA's first DeNovo marketing authorization for OTC respiratory triple test kits by the subsidiary, American Hengjian Biotechnology, marks a milestone in the company's development history [1][3]. Group 1: FDA Authorization and Product Details - American Hengjian received its first OTC flu test kit marketing authorization through traditional pre-market review on October 8, eliminating reliance on emergency use authorization [1]. - The newly authorized product ranks among the top in sensitivity and specificity compared to other OTC flu and COVID-19 test kits that were launched under emergency use authorization [1]. - The FDA's announcement highlighted that this is the first OTC flu and COVID-19 combined home test kit authorized without emergency use, establishing a new regulatory category for similar devices [2]. Group 2: Company Background and Achievements - American Hengjian, a subsidiary of Oriental Bio, is located in Houston, Texas, and focuses on the research, development, production, and sales of diagnostic reagents and instruments for infectious diseases and tumor markers [2]. - The company has made significant progress in respiratory test reagents and instruments, achieving FDA authorization for various products, including the flu and COVID-19 triple test kit [2]. - Both Oriental Bio and American Hengjian have large production bases and automated assembly lines in China and Texas, with a daily production capacity exceeding 10 million tests in both locations [2]. Group 3: Team and R&D Efforts - The company emphasizes the recruitment and training of high-tech talent to build a first-class team dedicated to addressing global respiratory and COVID-19 outbreaks [3]. - The achievement of the FDA DeNovo certificate for the COVID-19/flu triple test reflects the collective efforts of the company's teams in the U.S. and China, showcasing their commitment to high-quality and reliable diagnostic reagents [3].

证券代码：688298 证券简称：东方生物 公告编号：2024-063 浙江东方基因生物制品股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 13 日(星期三)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 06 日(星期三)至 11 月 12 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@orientgene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 浙江东方基因生物制品股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2024 年 ...

Financial Performance - Revenue for Q3 2024 reached ¥239,378,629.93, an increase of 58.92% compared to the same period last year[2] - Net profit attributable to shareholders was -¥110,548,767.87, a decrease of 3.13% year-on-year[2] - Basic earnings per share for the year-to-date were -¥1.32, a decrease of 267.98% compared to the previous year[3] - The company experienced a 262.17% decrease in net profit attributable to shareholders from the beginning of the year to the reporting period[6] - The net profit for the third quarter of 2024 was -274,227,549.60 RMB, compared to -67,266,359.19 RMB in the same period of 2023, indicating a significant increase in losses[19] - Operating profit for the third quarter was -282,546,252.62 RMB, a decline from -44,437,855.43 RMB year-over-year[19] - The company reported a total comprehensive loss of -291,781,782.68 RMB for the third quarter, compared to -42,388,332.53 RMB in the same quarter of 2023[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,234,404,013.88, down 8.47% from the end of the previous year[3] - The company's total assets decreased to ¥8,234,404,013.88 from ¥8,995,951,150.74[17] - The total liabilities decreased to ¥1,183,176,692.28 from ¥1,446,223,002.71, indicating improved financial health[16] - The company's equity attributable to shareholders was ¥6,880,382,859.03, down 7.47% from the previous year[3] - The company's equity attributable to shareholders decreased to ¥6,880,382,859.03 from ¥7,436,071,401.35, reflecting changes in retained earnings[17] - Short-term borrowings decreased to ¥186,735,657.38 from ¥198,221,896.67, showing a reduction in reliance on debt[16] Cash Flow - Cash flow from operating activities for the year-to-date increased by 77.33% compared to the previous year[7] - The cash flow from operating activities showed a net outflow of -367,152,854.58 RMB, an improvement from -1,619,675,103.24 RMB in the previous year[21] - The company reported a financial expense of -¥45,920,433.50, a significant improvement from -¥252,109,103.42 in the previous year, indicating better financial management[18] - The net cash flow from financing activities was -374,987,236.57, a significant decrease compared to 35,322,755.53 in the previous period[22] - Cash and cash equivalents at the end of the period totaled 1,942,768,528.39, down from 4,844,939,391.44 at the beginning of the period[22] - The net decrease in cash and cash equivalents was -985,834,813.78, compared to -1,711,620,452.84 in the previous period[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10[8] - The company’s major shareholders include Anji Fulanglai Import and Export Trade Co., Ltd., holding 39.31 million shares, representing 19.50% of the total shares[10] - The top ten unrestricted shareholders collectively hold a significant portion of the company's shares, with the largest shareholder controlling 39.31 million shares[10] Research and Development - R&D expenses totaled ¥63,579,055.71, accounting for 26.56% of revenue, a decrease of 16.19% compared to the previous year[3] - Research and development expenses rose to ¥209,881,229.54, compared to ¥188,135,533.21 in the previous year, indicating a focus on innovation[18] Market and Product Development - The company achieved FDA De Novo certification for its Healgen Rapid Check COVID-19/flu A&B Antigen Test on October 7, 2024, marking it as the first OTC testing product to receive this certification in the U.S.[13] - The company has established a strategic focus on expanding its market presence in the U.S. for respiratory testing products[13] - The company plans to continue monitoring the market demand for its newly certified products in the U.S. and actively promote sales[13] Share Buyback and Financial Management - The company completed a share buyback program, repurchasing 8.4036 million shares, which is 4.17% of the total share capital, with a total expenditure of approximately RMB 277 million[13] - The company’s share buyback was approved with a budget of between RMB 250 million and RMB 300 million, aimed at employee stock ownership plans or equity incentives[13] Other Financial Metrics - The company reported a total of ¥32,035,741.30 in non-recurring gains and losses for the current period[5] - Total operating revenue for the first three quarters of 2024 reached ¥657,613,863.02, a slight increase from ¥652,171,856.12 in the same period of 2023[18] - Total operating costs increased significantly to ¥1,015,757,409.45 from ¥718,719,790.87 year-on-year[18] - The company reported an increase in accounts receivable, with notes receivable rising to RMB 1.80 million from RMB 1.57 million, an increase of 14.0%[14] - Accounts receivable increased to ¥271,051,469.49 from ¥206,163,074.65, reflecting a growing customer base[15] - Inventory levels rose to ¥427,260,228.20, up from ¥346,775,187.97, suggesting increased production or stockpiling[15] - Interest income decreased to 83,735,447.92 RMB from 158,298,097.02 RMB year-over-year, reflecting a decline of approximately 47%[19] - The company reported a total of 4,996,672.21 RMB in other income, down from 8,465,436.48 RMB in the previous year, indicating a decrease of about 41%[19] - The company distributed dividends and interest payments totaling 10,939,543.43, down from 390,641,397.99 in the previous period[22] Accounting Changes - The company has adopted new accounting standards starting from 2024, which may affect the financial statements[22]

证券代码：688298 证券简称：东方生物 公告编号：2024-061 浙江东方基因生物制品股份有限公司 对外投资公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资标的名称：东方基因全球数字化研发创新总部项目（以下简称"本 项目"） 投资金额：项目总投资 15 亿元，固定资产投资 12 亿元 相关风险提示： 1、本项目的投资和实施，以合法取得本项目选址用地，以及完成各项建设 许可/备案/批复等合法手续，作为本项目实施的前置条件，具有一定的不确定性。 2、项目建设进程、运营能力和预期经营效益存在一定的不确定性。 本议案无需提交股东大会审议，本项目投资不构成关联交易，不构成《上市 公司重大资产重组管理办法》《科创板上市公司重大资产重组特别规定》等规定 的重大资产重组。 一、对外投资概述 （一）对外投资的基本情况 浙江东方基因生物制品股份有限公司（以下简称"东方生物"、"东方基因"、 "公司"）下属全资子公司上海万山水生物科技有限公司（以下简称"上海万山 水"、"乙方"）作为"东方基因全球数字化研发创新总 ...